A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol)

• Status: Recruiting
• Trial end date: 2026-04-27

Summary

This a phase 2 multi-cohort, un-controlled, non-randomized, open-label, multi-center study assessing the antitumor activity and safety of non-alpha interleukin (IL-2) SAR444245 in participants aged 12 years and older with relapsed or refractory B cell lymphoma. This study is structured as a master protocol with additional sub-studies (cohorts) to be added for the investigation of SAR444245 with other anticancer therapies.

Substudy 1-Cohort A aims to establish safety and preliminary anti-tumor activity for non-alpha interleukin (IL-2) SAR444245 combined with the anti-PD1 antibody, pembrolizumab in trial participants with classic Hodgkin lymphoma (cHL) who are anti-programmed cell death-ligand (PD)-(L)1-naïve and have received at least 2 or 3 lines of systemic therapy.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab